Equities research analysts expect Affimed N.V. (NASDAQ:AFMD) to report $970,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Affimed N.V.’s earnings. The highest sales estimate is $1.77 million and the lowest is $530,000.00. Affimed N.V. reported sales of $1.05 million in the same quarter last year, which would suggest a negative year over year growth rate of 7.6%. The firm is expected to report its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Affimed N.V. will report full year sales of $970,000.00 for the current fiscal year, with estimates ranging from $1.10 million to $13.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $12.18 million per share, with estimates ranging from $2.13 million to $32.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Affimed N.V..

Affimed N.V. (NASDAQ:AFMD) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. The firm had revenue of $0.51 million for the quarter, compared to analyst estimates of $1.31 million. Affimed N.V. had a negative return on equity of 73.85% and a negative net margin of 978.31%. The business’s revenue for the quarter was down 75.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.24) earnings per share.

A number of equities research analysts recently commented on the stock. SunTrust Banks, Inc. assumed coverage on shares of Affimed N.V. in a report on Thursday, July 13th. They issued a “buy” rating and a $7.00 price target on the stock. ValuEngine raised shares of Affimed N.V. from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $2.50 price target on shares of Affimed N.V. in a report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Affimed N.V. currently has a consensus rating of “Hold” and an average target price of $5.38.

Several large investors have recently bought and sold shares of AFMD. Wellington Management Group LLP raised its holdings in shares of Affimed N.V. by 30.8% in the 1st quarter. Wellington Management Group LLP now owns 5,413,291 shares of the biopharmaceutical company’s stock worth $12,450,000 after purchasing an additional 1,274,852 shares during the period. Virtu KCG Holdings LLC bought a new stake in shares of Affimed N.V. in the 2nd quarter worth approximately $144,000. Nationwide Fund Advisors raised its holdings in shares of Affimed N.V. by 4.6% in the 2nd quarter. Nationwide Fund Advisors now owns 506,199 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 22,172 shares during the period. Finally, Creative Planning raised its holdings in shares of Affimed N.V. by 7.7% in the 2nd quarter. Creative Planning now owns 70,000 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 5,000 shares during the period. 42.34% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/19/brokerages-anticipate-affimed-n-v-afmd-will-announce-quarterly-sales-of-970000-00.html.

Shares of Affimed N.V. (AFMD) opened at 2.15 on Thursday. Affimed N.V. has a 1-year low of $1.65 and a 1-year high of $2.95. The company’s market cap is $94.47 million. The firm has a 50-day moving average price of $2.15 and a 200 day moving average price of $2.20.

Affimed N.V. Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get a free copy of the Zacks research report on Affimed N.V. (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Affimed N.V. (NASDAQ:AFMD)

Receive News & Ratings for Affimed N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed N.V. and related companies with MarketBeat.com's FREE daily email newsletter.